These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
440 related articles for article (PubMed ID: 31172659)
1. Nanovaccines for cancer immunotherapy. Zhang Y; Lin S; Wang XY; Zhu G Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Sep; 11(5):e1559. PubMed ID: 31172659 [TBL] [Abstract][Full Text] [Related]
2. Nanovaccines: An effective therapeutic approach for cancer therapy. Gurunathan S; Thangaraj P; Wang L; Cao Q; Kim JH Biomed Pharmacother; 2024 Jan; 170():115992. PubMed ID: 38070247 [TBL] [Abstract][Full Text] [Related]
3. Efficient Nanovaccine Delivery in Cancer Immunotherapy. Zhu G; Zhang F; Ni Q; Niu G; Chen X ACS Nano; 2017 Mar; 11(3):2387-2392. PubMed ID: 28277646 [TBL] [Abstract][Full Text] [Related]
4. Biogenic nanoparticles as immunomodulator for tumor treatment. Cheng K; Kang Q; Zhao X Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Nov; 12(6):e1646. PubMed ID: 32464709 [TBL] [Abstract][Full Text] [Related]
5. Nanovaccines in cancer immunotherapy: Focusing on dendritic cell targeting. Achmad H; Saleh Ibrahim Y; Mohammed Al-Taee M; Gabr GA; Waheed Riaz M; Hamoud Alshahrani S; Alexis Ramírez-Coronel A; Turki Jalil A; Setia Budi H; Sawitri W; Elena Stanislavovna M; Gupta J Int Immunopharmacol; 2022 Dec; 113(Pt B):109434. PubMed ID: 36402068 [TBL] [Abstract][Full Text] [Related]
6. Nanovaccines: Immunogenic tumor antigens, targeted delivery, and combination therapy to enhance cancer immunotherapy. Jahanafrooz Z; Oroojalian F; Mokhtarzadeh A; Rahdar A; Díez-Pascual AM Drug Dev Res; 2024 Aug; 85(5):e22244. PubMed ID: 39138855 [TBL] [Abstract][Full Text] [Related]
7. Emerging advances in synthetic cancer nano-vaccines: opportunities and challenges. Ahmad MZ; Ahmad J; Haque A; Alasmary MY; Abdel-Wahab BA; Akhter S Expert Rev Vaccines; 2020 Nov; 19(11):1053-1071. PubMed ID: 33315512 [No Abstract] [Full Text] [Related]
8. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy. Aikins ME; Xu C; Moon JJ Acc Chem Res; 2020 Oct; 53(10):2094-2105. PubMed ID: 33017150 [TBL] [Abstract][Full Text] [Related]
9. Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy. Su T; Cheng F; Qi J; Zhang Y; Zhou S; Mei L; Fu S; Zhang F; Lin S; Zhu G Adv Sci (Weinh); 2022 Aug; 9(23):e2201895. PubMed ID: 35712773 [TBL] [Abstract][Full Text] [Related]
10. Dual-Targeted Self-Adjuvant Heterocyclic Lipidoid@Polyester Hybrid Nanovaccines for Boosting Cancer Immunotherapy. Liu Z; Liu B; Feng Y; Zhao L; Wang Q; He H; Yin T; Zhang Y; Yang L; Gou J; Tang X ACS Nano; 2024 Jun; 18(24):15557-15575. PubMed ID: 38837909 [TBL] [Abstract][Full Text] [Related]
11. Nanovaccine-based strategies for lymph node targeted delivery and imaging in tumor immunotherapy. He A; Li X; Dai Z; Li Q; Zhang Y; Ding M; Wen ZF; Mou Y; Dong H J Nanobiotechnology; 2023 Jul; 21(1):236. PubMed ID: 37482608 [TBL] [Abstract][Full Text] [Related]
12. Improved cancer immunotherapy strategies by nanomedicine. Guo S; Feng J; Li Z; Yang S; Qiu X; Xu Y; Shen Z Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(3):e1873. PubMed ID: 36576112 [TBL] [Abstract][Full Text] [Related]
13. Unlocking the power of nanomedicine: Cell membrane-derived biomimetic cancer nanovaccines for cancer treatment. Zhao G; Wang S; Nie G; Li N Med; 2024 Jul; 5(7):660-688. PubMed ID: 38582088 [TBL] [Abstract][Full Text] [Related]
14. Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy. Cai T; Liu H; Zhang S; Hu J; Zhang L J Nanobiotechnology; 2021 Nov; 19(1):389. PubMed ID: 34823541 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy and Prevention of Cancer by Nanovaccines Loaded with Whole-Cell Components of Tumor Tissues or Cells. Ma L; Diao L; Peng Z; Jia Y; Xie H; Li B; Ma J; Zhang M; Cheng L; Ding D; Zhang X; Chen H; Mo F; Jiang H; Xu G; Meng F; Zhong Z; Liu M Adv Mater; 2021 Oct; 33(43):e2104849. PubMed ID: 34536044 [TBL] [Abstract][Full Text] [Related]
16. Nanoparticle delivery systems in cancer vaccines. Krishnamachari Y; Geary SM; Lemke CD; Salem AK Pharm Res; 2011 Feb; 28(2):215-36. PubMed ID: 20721603 [TBL] [Abstract][Full Text] [Related]
17. Application of biomimetic nanovaccines in cancer immunotherapy: A useful strategy to help combat immunotherapy resistance. Xu Z; Zhou H; Li T; Yi Q; Thakur A; Zhang K; Ma X; Qin JJ; Yan Y Drug Resist Updat; 2024 Jul; 75():101098. PubMed ID: 38833804 [TBL] [Abstract][Full Text] [Related]
18. Nanobiomaterial-based vaccination immunotherapy of cancer. Chen F; Wang Y; Gao J; Saeed M; Li T; Wang W; Yu H Biomaterials; 2021 Mar; 270():120709. PubMed ID: 33581608 [TBL] [Abstract][Full Text] [Related]
19. Advances in Cancer Nanovaccines: Harnessing Nanotechnology for Broadening Cancer Immune Response. Wang QT; Liu YX; Wang J; Wang H ChemMedChem; 2023 Jul; 18(13):e202200673. PubMed ID: 37088719 [TBL] [Abstract][Full Text] [Related]
20. Nanoparticle-Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions. Liu J; Zhang R; Xu ZP Small; 2019 Aug; 15(32):e1900262. PubMed ID: 30908864 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]